Affordable Access

deepdyve-link
Publisher Website

[Bortezomib-induced acute neutrophilic dermatosis].

Authors
  • Tanguy-Schmidt, A1
  • Avenel-Audran, M
  • Croué, A
  • Lissandre, S
  • Dib, M
  • Zidane-Marinnes, M
  • Moles, M-P
  • Hunault-Berger, M
  • 1 Service des maladies du sang, CHU d'Angers, 49933 Angers cedex 09, France. , (France)
Type
Published Article
Journal
Annales de Dermatologie et de Vénéréologie
Publisher
Elsevier
Publication Date
May 01, 2009
Volume
136
Issue
5
Pages
443–446
Identifiers
DOI: 10.1016/j.annder.2008.11.021
PMID: 19442803
Source
Medline
Language
French
License
Unknown

Abstract

Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients. We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present. The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.

Report this publication

Statistics

Seen <100 times